Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.

doi:10.1126/scitranslmed.3007205

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.

Science translational medicine - 18 Dec 2013

Yasuda Hiroyuki, Park Eunyoung, Yun Cai-Hong, Sng Natasha J, Lucena-Araujo Antonio R, Yeo Wee-Lee, Huberman Mark S, Cohen David W, Nakayama Sohei, Ishioka Kota, Yamaguchi Norihiro, Hanna Megan, Oxnard Geoffrey R, Lathan Christopher S, Moran Teresa, Sequist Lecia V, Chaft Jamie E, Riely Gregory J, Arcila Maria E, Soo Ross A, Meyerson Matthew, Eck Michael J, Kobayashi Susumu S, Costa Daniel B

Abstract excerpt

Epidermal growth factor receptor (EGFR) gene mutations (G719X, exon 19 deletions/insertions, L858R, and L861Q) predict favorable responses to EGFR tyrosine kinase inhibitors (TKIs) in advanced non-small cell lung cancer (NSCLC). However, EGFR exon 20 insertion mutations (~10% of all EGFR mutations) are generally associated with insensitivity to available TKIs (gefitinib, erlotinib, and afatinib). The basis of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Crystallography, X-Ray

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Genes, erbB-1

Share to Mutagenesis, Insertional

Share to Quinazolines

Share to Structural Homology, Protein

Share to Translational Research, Biomedical

Source

Open in PubMed Open full text

Identifiers

PMID: 24353160
DOI: 10.1126/scitranslmed.3007205
PMCID: PMC3954775

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.PMID 24353160Read ↗

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancerSemantic proximity Read ↗

Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non-small cell lung cancer.Semantic proximity Read ↗

A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments.Semantic proximity Read ↗

Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.Semantic proximity Read ↗

[Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations].Semantic proximity Read ↗

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutationsSemantic proximity Read ↗

Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.Semantic proximity Read ↗

EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies.Semantic proximity Read ↗

[The research status and development trend of EGFR gene exon 20 insertion mutant non-small cell lung cancer].Semantic proximity Read ↗

EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios.Semantic proximity Read ↗

EGFR exon 20 insertion mutations in non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.